Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a report issued on Monday morning. The brokerage issued a hold rating on the medical research company’s stock.

Separately, BTIG Research upgraded Accelerate Diagnostics to a “strong-buy” rating in a research report on Wednesday, December 11th.

Accelerate Diagnostics Trading Down 1.3 %

NASDAQ:AXDX opened at $1.12 on Monday. The company has a market capitalization of $27.92 million, a P/E ratio of -0.39 and a beta of 0.55. The firm has a 50-day moving average price of $1.17 and a two-hundred day moving average price of $1.46. Accelerate Diagnostics has a twelve month low of $0.73 and a twelve month high of $2.09.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC increased its holdings in Accelerate Diagnostics by 160.6% during the 4th quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock worth $128,000 after purchasing an additional 65,984 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Accelerate Diagnostics during the fourth quarter worth approximately $27,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Accelerate Diagnostics in the third quarter worth $34,000. Finally, Geode Capital Management LLC raised its holdings in Accelerate Diagnostics by 6.9% in the fourth quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock valued at $163,000 after acquiring an additional 8,777 shares in the last quarter. Hedge funds and other institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.